UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Head and Neck Cancer

The New England journal of medicine, 2020-01, Vol.382 (1), p.60-72

2020

Volltextzugriff (PDF)

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

The oncologist (Dayton, Ohio), 2015-07, Vol.20 (7), p.812-822

2015

Volltextzugriff (PDF)

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Clinical cancer research, 2017-06, Vol.23 (12), p.3158-3167

2017

Volltextzugriff (PDF)

Sunitinib: From Rational Design to Clinical Efficacy

Journal of clinical oncology, 2007-03, Vol.25 (7), p.884-896

2007

Volltextzugriff (PDF)

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

The New England journal of medicine, 2012-06, Vol.366 (26), p.2455-2465

2012

Volltextzugriff (PDF)

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

The New England journal of medicine, 2014-03, Vol.370 (13), p.1189-1197

2014

Volltextzugriff (PDF)

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

Clinical cancer research, 2020-02, Vol.26 (4), p.837-845

2020

Volltextzugriff (PDF)

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1363-1372

2018

Volltextzugriff (PDF)

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Journal of thoracic oncology, 2018-11, Vol.13 (11), p.1733-1742

2018

Volltextzugriff (PDF)

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma

Neuro-oncology (Charlottesville, Va.), 2017-01, Vol.19 (1), p.i1-i24

2017

Volltextzugriff (PDF)

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

Clinical cancer research, 2017-09, Vol.23 (17), p.4959-4969

2017

Volltextzugriff (PDF)

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

Nature (London), 2011-09, Vol.477 (7362), p.99-102

2011

Volltextzugriff (PDF)

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

Journal of clinical oncology, 2010-02, Vol.28 (5), p.780-787

2010

Volltextzugriff (PDF)

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy

Cancer treatment reviews, 2017-04, Vol.55, p.181-189

2017

Volltextzugriff (PDF)

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Journal of clinical oncology, 2016-07, Vol.34 (21), p.2460-2467

2016

Volltextzugriff (PDF)

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

British journal of cancer, 2018-07, Vol.119 (2), p.153-159

2018

Volltextzugriff (PDF)

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

Journal of clinical oncology, 2016-11, Vol.34 (32), p.3838-3845

2016

Volltextzugriff (PDF)

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

The lancet oncology, 2019-10, Vol.20 (10), p.1395-1408

2019

Volltextzugriff (PDF)

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-09, Vol.23 (18), p.5349-5357

2017

Volltextzugriff (PDF)

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

The lancet oncology, 2017-02, Vol.18 (2), p.212-220

2017

Volltextzugriff (PDF)

Head and Neck Cancer. Reply

The New England journal of medicine, 2020-05, Vol.382 (20), p.e57-e57

Chow, Laura Q M

2020

Volltextzugriff (PDF)

Dry powders for inhalation containing monoclonal antibodies made by thin-film freeze-drying

International journal of pharmaceutics, 2022-04, Vol.618, p.121637-121637, Article 121637

2022

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(57)

Sprache

Englisch
(57)

Erscheinungsjahr

n.n

Thema

Science & Technology
(47)
Life Sciences & Biomedicine
(46)
Humans
(42)
Oncology
(39)
Female
(30)
Male
(28)
Middle Aged
(27)
Aged
(24)
Adult
(21)
Tumors
(18)
Immunotherapy
(15)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(14)
Aged, 80 And Over
(12)
Patients
(12)
Lung Neoplasms - Drug Therapy
(11)
Monoclonal Antibodies
(11)
Cancer
(10)
Neoplasms - Drug Therapy
(10)
Squamous Cell Carcinoma
(10)
Targeted Cancer Therapy
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Head and Neck Cancer

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Sunitinib: From Rational Design to Clinical Efficacy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)

Head and Neck Cancer. Reply

Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Dry powders for inhalation containing monoclonal antibodies made by thin-film freeze-drying

Suchergebnisse filtern